SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Murray T,Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Hellman K,Silfversward C,Nilsson B,Hellstrom AC,Frankendal B,Pettersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. Int J Gynecol Cancer. 2004; 14: 491501.
  • 3
    Carter JJ,Madeleine MM,Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001; 61: 19341940.
  • 4
    Daling J,Madeleine M,Schwartz S, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263270.
  • 5
    Daling JR,Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. In: MunozN,BoschFX,ShahKV,MeheusA, eds. The Epidemiology of Human Papillomavirus and Cervical Cancer (IARC Scientific Publication No. 119). Lyon, France: IARC; 1992: 223241.
  • 6
    Brinton LA,Nasca PC,Mallin K, et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol. 1990; 38: 4954.
  • 7
    McFarlane MJ,Feinstein AR,Horwitz RI. Diethylstilbestrol and clear cell vaginal carcinoma. Reappraisal of the epidemiologic evidence. Am J Med. 1986; 81: 855863.
  • 8
    Franco EL. Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin North Am. 1996; 23: 597623.
  • 9
    Merino MJ. Vaginal cancer: the role of infectious and environmental factors. Am J Obstet Gynecol. 1991; 165(4 pt 2): 12551262.
  • 10
    Srodon M,Stoler MH,Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30: 15131518.
  • 11
    Hampl M,Sarajuuri H,Wentzensen N,Bender H,Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 13611368.
  • 12
    Parkin D,Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S11S25.
  • 13
    Castle PE,Schiffman M,Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis. 2004; 190: 458467.
  • 14
    Schiffman M,Castle PE,Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890907.
  • 15
    Dodge JA,Eltabbakh GH,Mount SL, et al. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001; 83: 363369.
  • 16
    Aho M,Vesterinen E,Meyer B, et al. Natural history of vaginal intraepithelial neoplasia. Cancer. 1991; 68: 195197.
  • 17
    Indermaur MD,Martino MA,Fiorica JV, et al. Upper vaginectomy for the treatment of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2005; 193: 577580; discussion 580–581.
  • 18
    Moscicki AB,Hills N,Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001; 285: 29953002.
  • 19
    Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369: 16931702.
  • 20
    Watson M,Saraiya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 28412854.
  • 21
    Harwell TS,Miller SH,Lemons DL, et al. Cancer incidence in Montana: rates for American Indians exceed those for whites. Am J Prev Med. 2006; 30: 493497.
  • 22
    YoungJJ,RoffersS,RiesL,FritzA,HurlbutA, eds. SEER Summary Staging Manual—2000: Codes and Coding Instructions. National Cancer Institute. NIH Publication No. 01-4969, Bethesda, Md: National Cancer Institute; 2001.
  • 23
    Surveillance, Epidemiology, and End Results Program. Extent of Disease: Code and Coding Instructions. Bethesda, Md: National Institutes of Health, National Cancer Institute; 1977.
  • 24
    Howe H,Jamison P,Havener L,Chen V,Ries L. Site-specific comparison of summary stage 1977 and summary stage 2000 coding. Available at: http//www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=397. Accessed on July 23, 2008.
  • 25
    Tiwari RC,Clegg LX,Zou Z,Tiwari RC,Clegg LX,Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547569.
  • 26
    Parkin DM,Whelan SL,Ferlay J,Teppo L,Thomas D,Thomas DB.Cancer Incidence in Five Continents. Vol VIII. Lyon, France: International Agency for Research on Cancer; 2002.
  • 27
    Shambaugh E,Young JJr,Zippin C,Lum D,Akers C,Weiss M. SEER Program Self-Instructional Manual for Cancer Registrars. Book 7: Statistics and Epidemiology for Cancer Registrars. National Cancer Institute. NIH Publication No.94-3766. Bethesda, Md: National Institutes of Health; 1994.
  • 28
    Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050, US Bureau of the Census, Current Population Reports, P25-1130. Washington, DC: US Government Printing Office; 1996.
  • 29
    Revzina NV,Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005; 16: 528537.
  • 30
    Kahn JA,Lan D,Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007; 110: 8795.
  • 31
    Magnusson P,Sparen P,Gyllensten U. Genetic link to cervical tumours. Nature. 1999; 400: 2930.
  • 32
    Levi F,Randimbison L,La Vecchia C. Descriptive epidemiology of vulvar and vaginal cancers in Vaud, Switzerland, 1974-1994. Ann Oncol. 1998; 9: 12291232.
  • 33
    Heusch WL,Maneckjee R,Heusch WL,Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis. 1998; 19: 551556.
  • 34
    Wright SC,Zhong J,Zheng H, et al. Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J. 1993; 7: 10451051.
  • 35
    Poppe WA,Peeters R,Daenens P, et al. Tobacco smoking and the uterine cervix: cotinine in blood, urine and cervical fluid. Gynecol Obstet Invest. 1995; 39: 110114.
  • 36
    Gunnell AS,Tran TN,Torrang A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006; 15: 21412147.
  • 37
    Hildesheim A,Han C,Brinton L, et al. Sexually transmitted agents and risk of carcinoma of the vagina. Int J Gynecol Cancer. 1997; 7: 251255.
  • 38
    Kleinerman R,Kosary C,Hildesheim A. Chapter 8: new malignancies following cancer of the cervix uteri, vagina, and vulva. In: CurtisRE,FreedmanDM,RonE, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publication No. 05-5302. Bethesda, Md: National Cancer Institute; 2006.
  • 39
    Pride GL,Buchler DA. Carcinoma of vagina 10 or more years following pelvic irradiation therapy. Am J Obstet Gynecol. 1977; 127: 513517.
  • 40
    Ryberg M,Lundell M,Nilsson B,Pettersson F. Malignant disease after radiation treatment of benign gynaecological disorders. A study of a cohort of metropathia patients. Acta Oncol. 1990; 29: 563567.
  • 41
    Chyle V,Zagars GK,Wheeler JA,Wharton JT,Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1996; 35: 891905.
  • 42
    Freeman G,Lethbridge-Cejku M. Access to health care among Hispanic or Latino women: United States, 2000-2002. Adv Data. 2006;( 368): 125.
  • 43
    Howe H,Wu X,Edwards B, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006; 107: 17111742.
  • 44
    Kagawa-Singer M,Pourat N. Asian American and Pacific Islander breast and cervical carcinoma screening rates and Healthy People 2000 objectives. Cancer. 2000; 89: 696705.
  • 45
    Chen MJ. Cancer health disparities among Asian Americans: what we do and what we need to do. Cancer. 2005; 104( 12 suppl): 28952902.
  • 46
    U.S. Department of Health and Human Services. 2004 National Healthcare Disparities Report. Rockville, Md: Agency for Healthcare Research and Quality; 2004.
  • 47
    Swan J,Breen N,Coates R,Rimer B. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 15281540.
  • 48
    Hewitt M,Devesa S,Breen N. Cervical cancer screening among US women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270278.
  • 49
    Saslow D,Runowicz C,Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342362.
  • 50
    US Preventive Services Task Force. Cervical Cancer—Screening. Release date, January 2003. Available at: http//www.ahrq.gov/clinic/uspstf/uspscerv.htm. Accessed July 30, 2007.
  • 51
    Kolb B,Wallace AM,Hill D,Royce M. Disparities in cancer care among racial and ethnic minorities. Oncology (Williston Park). 2006; 20: 12561261; discussion 1261, 1265, 1268–1270.
  • 52
    Hamel MB,Teno JM,Goldman L, et al. Patient age and decisions to withhold life-sustaining treatments from seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med. 1999; 130: 116125.
  • 53
    SEER. The SEER Program Code Manual, 3rd ed, revision 1 (updated January 2003). NIH Publication No. 98-1999. Bethesda, Md: National Institutes of Health, National Cancer Institute; 1998.
  • 54
    HavenerL,HultstromD, eds.Standard for Cancer Registries Volume II: Data Standard and Data Dictionary, 11th ed, version 11.1. Springfield, Ill: North American Association of Central Cancer Registries; 2006.